Woman dances with Alaska mountains behind.

Know Your History. Save Your Future.

Any Mountain Expedition Team

The Any Mountain project is dedicated to funding research on the prevention and early detection of ovarian cancer. This research is being conducted by an incredible team of gynecologic oncology leaders from around the country.

We are creating the first international surgical ovarian cancer prevention trial which could revolutionize how women choose to decrease their risk of ovarian cancer. Next up: novel efforts to improve early detection, treatment and prevention.  

Any Mountain is expressly committed to ending racism within healthcare and beyond. Research priority will be given to projects addressing intersections of racial justice and ovarian cancer. Ending racism saves lives.

How the Dollars Raised for the Everest Trip are Being Used

Together, we raised over $500,000 for ovarian cancer awareness, prevention, and early detection research.

More than 700 people donated between $10 – $75,000 dollars



total raised

After expenses…


to Research


to Creative Awareness


to Project Administration

The research money raised went to the Any Mountain Expedition research team lead by Dr. Elizabeth Swisher from University of Washington and Dr. Karen Lu from MD Anderson. The allocation of research funds is being overseen the Minnesota Ovarian Cancer Alliance under the leadership of their Executive Director Kathleen Gavin.


MOCA is distributing funds raised by the Any Mountain trek to Mt. Everest to cancer centers throughout the U.S. to support the expansion of the international TUBA-WISP II trial. This surgical prevention trial, managed by MD Anderson Cancer Center, gives women, who are at high risk for ovarian cancer due to genetic mutations, the option of a two-step procedure to reduce their risk. By having their fallopian tubes surgically removed first (salpingectomy) with a delayed ovary removal (oophorectomy), women are able to preserve hormonal function longer, thereby maintaining cardiovascular protection, sexual function and other benefits.

The Any Mountain funding is being used to open sites across the country expanding access to diverse populations.

The Any Mountain TUBA-WISP II trial is currently open and enrolling patients at:

  • MD Anderson (Houston, Texas) 
  • Mayo Clinic (Rochester, MN) 
  • Memorial Sloan Kettering (New York City) 
  • University of Washington (Seattle) 
  • Dana Farber Cancer Institute (Boston) 
  • Wahington University (St. Louis)  
  • Mount Sinai (NYC) 
  • University of Pennsylvania (Philadelphia)

For more information about the trial:

“My love you were with me, right by my side. Acting really tough, trying hard not to cry. You said to be strong, we’ll fight this head on. Take a leap of faith, and the journey’s begun.”


The Any Mountain project is made possible by Let Every Woman Know – Alaska and the Minnesota Ovarian Cancer Alliance.

Logo for ovarian cancer non-profit Let Every Woman Know-Alaska

Let Every Woman Know – Alaska

Let Every Woman Know – Alaska is dedicated to raising awareness, sharing information and saving lives by educating people in the Last Frontier and supporting women living with gynecologic cancers. It’s an Alaska-based non-profit, founded by Dr. Joanie Hope, which provides creative state-wide education, support, advocacy, and arts programs unique to the state’sdiverse communities.

Logo for ovarian cancer non-profit Minnesota Ovarian Cancer Alliance

Minnesota Ovarian Cancer Alliance

The Minnesota Ovarian Cancer Alliance (MOCA) is one of our key partners and committed to responsibly managing the funds raised for ovarian cancer research through the Any Mountain project. MOCA is a 501(c)3 non-profit organization dedicated to funding ovarian cancer research, providing support to the women and families affected by ovarian cancer, educating the medical community, and raising awareness of ovarian cancer.

“Been two years now and I’m still cancer free. I know I should be happy, but I don’t feel at ease. I need a vacation, from my life as a patient. Refuge from the steady blast of cancer’s damnation.”

Any Mountain Research Awards
October  2021

The following research projects were approved for one year of funding by Any Mountain in October 2021 and are currently underway. 



Principal Investigator: Karen Lu, MD at MD Anderson, Houston, TX

The TUBA-WISP II Study is a world-wide prevention study in high-risk women with multiple centers in the United States. This trial is designed to determine whether removing the fallopian tubes and delaying ovarian removal by 5 years is effective for reducing hereditary ovarian cancer risk, which would allow women to keep their ovarian function intact for a longer period of time.  Women self-select whether they want to undergo a standard removal of ovaries and fallopian tubes in one surgery or a new option to remove only the fallopian tubes and some years later remove the ovaries. Any Mountain funds will be used to finalize data forms, set up the national database, assist sites with IRB submissions and begin patient enrollment. Data from similar studies being done in other countries around the world will be pooled together to determine how safe and effective the new prevention option is for high risk women. Data from this trial could change the standard care for women at high risk of ovarian cancer

Understanding Decision Making for Risk Reducing Surgery                   


Principal Investigator: Kara Long Roche, MD at Memorial Sloan Kettering, NYC

This study will identify common themes and influential factors in the decision to undergo risk-reducing removal of the tubes and ovaries in young women at high genetic risk of developing ovarian cancer.  The researchers will determine sociodemographic, medical, and psychosocial factors that contribute to the decision-making process. Data from this study will help us better counsel women about options for managing an increased risk of ovarian cancer.

Predictor of Completion of Genetic Testing: An Ancillary Analysis of the MAGENTA Study


Principal Investigator: Barbara Norquist, MD at University of Washington, Seattle

THE MAGENTA study was a large trial that evaluated how much genetic counseling was needed to deliver testing for cancer genetic risk to women in their homes.  This ancillary analysis of the MAGENTA study will help us better understand why some people start the process, but then do not complete genetic testing at home by interviewing women who did and did not complete the testing process. Results from this study will help us identify concerns and barriers to genetic testing for cancer risk and inform future interventions to bring risk assessment to more people.